title: Autoimmune Blistering Diseases in the Elderly: Clinical Presentations and Management.
abstract: Elderly patients are more susceptible to the development of autoimmune blistering disorders such as bullous pemphigoid, mucous membrane pemphigoid, epidermolysis bullosa acquisita, and paraneoplastic pemphigus. This article focuses on the clinical aspects of the aforementioned autoimmune blistering diseases and highlights the important factors involved in treating elderly patients. It is essential for clinicians to offer individualized treatment plans for these patients to optimize outcomes, as elderly patients often have multiple co-morbidities, polypharmacy, and suboptimal socioeconomic status that can adversely influence adequate compliance.
authors.affiliation: Department of Dermatology, St. George Hospital, Gray St, Kogarah, Sydney, 2217, NSW, Australia.|University of New South Wales, Sydney, NSW, Australia.
authors.forename: Minhee
authors.initials: M
authors.lastname: Kim
authors.affiliation: Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland.
authors.forename: Luca
authors.initials: L
authors.lastname: Borradori
authors.affiliation: Department of Dermatology, St. George Hospital, Gray St, Kogarah, Sydney, 2217, NSW, Australia. d.murrell@unsw.edu.au.|University of New South Wales, Sydney, NSW, Australia. d.murrell@unsw.edu.au.
authors.forename: Dédée F
authors.initials: DF
authors.lastname: Murrell
mesh_terms: D000368:Aged; D000375:Aging / Q000187:drug effects / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D015897:Comorbidity; D016107:Epidermolysis Bullosa Acquisita / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010257:Paraneoplastic Syndromes / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000601:surgery; D010390:Pemphigoid, Benign Mucous Membrane / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D010391:Pemphigoid, Bullous / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D010392:Pemphigus / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D012872:Skin Diseases, Vesiculobullous / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology
chemical_list: D000911:Antibodies, Monoclonal; D005938:Glucocorticoids; D007166:Immunosuppressive Agents